オプションチェーンは、CARISMA Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、CARISMA Therapeuticsの市場センチメントを評価します。.

CARISMA Therapeutics (NASDAQ:CARM) 株価情報, オプションチェーン

CARISMA THERAPEUTICS INC

CARISMA Therapeutics

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics Inc

CARMAT ORD by Carmat

CARMELL CORPORATION WT EXP

CarMax Inc

Carmila SA

Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>), a clinical-stage diabetes and obesity medicines company, today announced updated preliminary clinical data from the ongoing Phase I COVALENT-103 trial of BMF-500 in adults with relapsed or refractory ("R/R") acute leukemia ("AL"). The results will be presented in a poster presentation at the European Hematology Association ("EHA") 2025 Congress in Milan, Italy.
The presentation by Dr. Farhad Ravandi of The University of Texas MD Anderson Cancer Center will highlight emerging safety, pharmacokinetics/pharmacodynamics, and early clinical activity data for BMF-500, a highly selective covalent FMS-like tyrosine kinase 3 ("FLT3") inhibitor, in heavily pretreated patients with R/R AL.
Key Results from the EHA 2025 Poster Presentation 27 patients were enrolled across two study arms, Arm A (no CYP3A4 inhibitor; n=10) and Arm B (CYP3A4 inhibitor; n=17). All patients had R/R AL, with a median of 4 prior lines of therapy. 18 of the 27 patients were FLT3 mutations ("FLT3m") while the other 9 patients had FLT3 wild-type AL. Frequent co-mutations included WT1, TP53, IDH1/2, and NRAS. All 18 FLT3m patients had failed gilteritinib in the R/R setting and 9 of the 18 had received at least two FLT3 inhibitors prior to study entry. 26 of 27 (96%) enrolled patients had also received and failed the BCL2 inhibitor venetoclax. Key findings include:
Clinical Activity Observed:
<ul>
<li>9 of 11 efficacy-evaluable FLT3m patients, defined as all patients enrolled who received at least one dose and had at least one disease assessment, showed bone marrow (BM) blast reduction; 5 of 11 achieved &gt;50% BM blast reduction.</li>
<li>1 FLT3m patient achieved complete remission with incomplete hematologic recovery (CRi), sustained for 6 cycles.</li>
<li>1 FLT3m patient achieved morphologic leukemia-free state (MLFS); response is ongoing.</li>
<li>1 FLT3m patient met all criteria for partial response (PR) except platelet recovery; categorized as near PR.</li>
<li>2 of 4 efficacy-evaluable FLT3 wild-type patients achieved durable disease control ≥120 days, with treatment ongoing for one patient.</li>
<li>Additional clinical improvements include reductions in peripheral blasts, transfusion dependency, and frequency of hydroxyurea use.</li>
</ul>
Pharmacokinetics/Pharmacodynamics:
<ul>
<li>FLT3 inhibition correlated with BMF-500 systemic exposures.</li>
<li>Bone marrow and plasma concentrations of BMF-500 and its metabolites were comparable, suggesting good compartmental penetration.</li>
</ul>
Survival:
<ul>
<li>Median overall survival (mOS) among all treated FLT3m patients (n=18) was 3.8 months (Arm A) and 3.5 months (Arm B) during dose escalation.</li>
<li>For the efficacy-evaluable FLT3m patients (n=12), the mOS for Arms A and B was 3.8 and 3.6 months, respectively during dose escalation.</li>
<li>These survival durations compare favorably to historical mOS of 2.1 months in patients with R/R FLT3m acute myeloid leukemia ("AML") post-failure with both gilteritinib and venetoclax.&nbsp;</li>
</ul>
Ongoing Dose Escalation:
<ul>
<li>Dose escalation continues at 200 mg BID (Arm A) and 75 mg BID (Arm B).</li>
<li>Based on observed activity and tolerability, further evaluation is underway to determine optimal biologic dose ("OBD") and recommended Phase II dose ("RP2D").</li>
</ul>
Safety and Tolerability
<ul>
<li>BMF-500 was generally well-tolerated across dose levels.</li>
<li>No dose-limiting toxicities (DLTs), QT prolongation, or discontinuations due to treatment-related adverse events were reported.</li>
<li>Escalation is ongoing without safety restrictions.</li>
</ul>
Following completion of the COVALENT-103 dose escalation phase in R/R AL patients with FLT3m, Biomea plans to conclude its internal development of BMF-500 in oncology and is actively exploring strategic partnerships to advance the program.

BMEA

Biomea Fusion Presents Updated Preliminary Clinical Data From Ongoing Phase I COVALENT-103 Trial Of BMF-500 In Adults With R/R Acute Leukemia, At EHA 2025 Congress

WIIM

SHEL

Shraes of energy stocks are trading higher following Israel's strikes on Iran, which have raised oil prices amid potential disruptions in production.

Biotech

Large Cap

News

Health Care

Contracts

General

AstraZeneca Has Entered A Strategic Research Collaboration With Shijiazhuang City-based CSPC Pharmaceuticals For Oral Candidates To Treat Diseases Across Multiple Indications, CSPC Will Receive An Upfront Payment Of $110M, And Is Also Eligible To Receive Up To $1.62B In Potential Development Milestone Payments And Up To $3.6B In Sales Milestone Payments, Plus Potential Single-digit Sales Based Royalties.

JBLU

Shares of airline stocks are trading lower following Israel's strikes on Iran, which have raised fuel prices and could cloud the travel demand outlook. The recent crash of an Air India flight could also be pressuring the sector.

GPUS

Hyperscale Data Projects $41M Annual Bitcoin Mining Run Rate Starting July 2025 With 19,200 Miners Across US Sites

BITF

CLSK

COIN

HIVE

MARA

MSTR

RIOT

Shares of crypto-linked stocks are trading lower following Israel's strikes on Iran, as risk-off sentiment pressures speculative assets.

$BTC

Bitcoin is trading lower following Israel's strikes on Iran, as the attacks could weigh on risk sentiment.

Shares of defense stocks are trading higher following Israel's strikes on Iran, which could lift demand outlook for military equipment.

Gold and silver are trading higher following Israel's attack on Iran, which has caused macro uncertainty and raised demand for safe-haven assets.

SPHL

Springview Singapore Says It Earns bizSAFE Level 4 Certification, Boosting Safety Standards And Market Opportunities

Oil is trading higher following Israel's strikes on Iran, which have caused supply uncertainty.

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock. In addition, Enliven intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of its common stock. All of the shares of common stock and pre-funded warrants are being offered by Enliven. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

ELVN

Enliven Therapeutics Launches $200M Public Offering With Option For $30M Upsize

Shares of defense stocks Rtx Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) and General Dynamics Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) climbed 4.6%, 4.2% and 1.2%, respectively, during Friday&#8217;s pre-market trading session amid Israel&#8217;s intensifying military <a href="https://www.benzinga.com/markets/equities/25/06/45921212/us-stocks-likely-to-open-lower-as-israel-strikes-iran-geopolitical-risks-offers-upside-for-dollar-say-experts">operations in Lebanon and Iran.</a>
What Happened: Israel recently initiated an invasion of Lebanon and executed <a href="https://www.benzinga.com/news/politics/25/06/45919250/trump-administration-distances-us-from-israels-strikes-on-iran-we-are-not-involved-says-marco-rubio">leaders of Iran&#8217;s IRGC. </a>This act provoked Iran to launch extensive strikes against targets within Israel. Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), the largest arms manufacturer globally, produces the F-35 aircraft, which Israel employs in its regular bombardments of Gaza. 
RTX Corporation, formerly Raytheon, the second-largest arms manufacturer, provides Israel with &#8220;bunker buster&#8221; bombs, which are prohibited in densely populated areas.
Meanwhile, General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>), another manufacturer of bunker busters, produces the BLU-109 bombs currently used by Israel.
SEE ALSO:&nbsp;<a href="https://benzinga.com/pressreleases/24/10/ab41310379/claritycheck-launches-innovative-reverse-lookup-tool-to-empower-users-against-digital-scams" target="_blank" rel="noreferrer noopener">ClarityCheck Launches Innovative Reverse Lookup Tool to Empower Users Against Digital Scams &#8211; Benzinga</a>
Why It Matters: The escalating tension in the Middle East has had a profound impact on global markets. Israel&#8217;s preemptive strike on Iran caused U.S. stock <a href="https://www.benzinga.com/markets/market-summary/25/06/45918802/middle-east-tensions-rattle-markets-us-stock-futures-slide-oil-jumps-8-gold-surges-above-3400-after-israel-strikes-iran">futures to slide</a>, oil prices to jump 8%, and gold to surge above $3,400.
Moreover, the Trump administration has distanced itself from Israel&#8217;s recent <a href="https://www.benzinga.com/news/politics/25/06/45919250/trump-administration-distances-us-from-israels-strikes-on-iran-we-are-not-involved-says-marco-rubio">military actions </a>against Iran. These strikes are expected to complicate President Donald Trump's efforts to negotiate a nuclear deal with Tehran.
Lastly, President Trump&#8217;s ambitious $175 billion plan <a href="https://www.benzinga.com/25/05/45548110/trumps-golden-dome-launches-new-era-for-defense-stocks-like-rtx-lockheed-martin-l3harris">to develop</a> a &#8220;Golden Dome&#8221; missile defense system announced in May is expected to usher in a new era for defense stocks like RTX, Lockheed Martin, and L3Harris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>).
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/tech/25/06/45897537/jamie-dimon-recalls-first-palantir-meeting-holy-christ-this-is-unbelievable-jpmorgan-now-has-600-ai-" target="_blank" rel="noreferrer noopener">Jamie Dimon Recalls First Palantir Meeting: &#8216;Holy Christ, This Is Unbelievable—&#8217; JPMorgan Now Has 600 AI Use Cases, $2 Billion Annual Investment On AI</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Lockheed Martin, RTX, General Dynamics And Other Defense Stocks Rise In Friday Pre-Market: What's Going On?

Kennedy Wilson Buys 265-Unit Seattle Multifamily Asset For $173M, , Expands Investment Platform With Japanese Partners

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved &nbsp;

Enliven Therapeutics Announced Updated Data From Phase 1 ENABLE Clinical Trial Evaluating ELVN-001 In Patients With Chronic Myeloid Leukemia In An Oral Presentation At European Hematology Association 2025 Congress

Cloudflare Prices $1.75B Convertible Notes Due 2030 With Optional $250M Upsize, Eyes $1.72B Net Proceeds

ZKH Group Limited ("ZKH" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>), a leading maintenance, repair and operations ("MRO") procurement service platform in China, today announced that its board of directors has authorized a new share repurchase program under which the Company may repurchase up to US$50 million worth of its shares (including American Depositary Shares) over the next 12 months, ending on June 13, 2026.
The share repurchases may be effected from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions, and will be implemented in accordance with applicable rules and regulations. The Company expects to fund the repurchases out of its existing cash balance.

ZKH Group Launches $50M Share Buyback Program Through June 2026, Funded From Cash Reserves

The new licensing deals include major agreements with:
<ul>
<li>France TV for the nature documentary series Planet Insect</li>
<li>The WNET Group (U.S.), home to America's flagship PBS station in New York, for several Curiosity originals</li>
<li>Canal+ (France) for the critically acclaimed Titans: The Rise of Wall Street</li>
<li>Kanopy for a wide range of factual and educational titles</li>
<li>SRC/Explora (Canada) for Planet Insect</li>
<li>SRF (Switzerland) for the innovation-driven series Oops, I Changed the World</li>
<li>V-Me TV (U.S. Hispanic) for a wide range of factual programming</li>
<li>NATV (Korea) for the environmental science program Fateful Planet</li>
<li>Al Jazeera (MENA) for the bold food culture series Eat Me or Try Not To</li>
</ul>

CURI

Curiosity Inc. Expands Global Reach With New International Content Licensing Deals

The U.S. Food and Drug Administration (FDA) expanded approval of Moderna Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) respiratory syncytial virus vaccine to adults aged 18-59 at increased risk for disease.
What Happened: The FDA on Thursday approved broader use of Moderna&#8217;s mRESVIA vaccine for younger at-risk adults based on late-stage trial results, reported Reuters.
The mRNA-based shot showed significant immune responses in adults with underlying health conditions and maintained a favorable safety profile. The vaccine was previously limited to adults 60 and older, where it demonstrated 79% efficacy against RSV symptoms.
Health Secretary Robert F. Kennedy Jr. simultaneously <a href="https://www.benzinga.com/news/health-care/25/06/45898417/rfk-jr-appoints-vaccine-critics-to-cdc-vaccine-panel-after-firing-entire-advisory-committee-report">appointed eight new members to the CDC&#8217;s Advisory Committee</a> on Immunization Practices, including prominent mRNA vaccine critics Robert Malone and Retsef Levi.
The health secretary fired all 17 existing panel members, claiming the need to <a href="https://www.benzinga.com/news/health-care/25/06/45853393/robert-kennedy-jr-axes-entire-cdc-vaccine-panel-to-restore-public-trust-pfizer-moderna-other-biotech-stocks-drop-in-after-hours-trading">&#8220;re-establish public confidence in vaccine science.&#8221;</a> The committee provides crucial guidance on vaccine recommendations that influence insurance coverage and policy.
The CDC currently recommends RSV vaccines for adults 75 and older, plus those 60-74 at increased risk. The final CDC recommendation remains pending for the expanded age group before availability.
See Also: <a href="https://www.benzinga.com/markets/economic-data/25/06/45919422/trumps-one-big-beautiful-bill-is-the-largest-redistribution-from-poor-to-rich-in-american-history-says-economist-justin-wolfers-amid-tax-cuts-spending-s">Trump&#8217;s &#8216;One Big, Beautiful Bill&#8217; Is &#8216;The Largest Redistribution From Poor To Rich In American History,&#8217; Says Economist Justin Wolfers Amid Tax Cuts, Spending Slashes And Tariffs</a>
Why It Matters: William Blair analysts noted the <a href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals">approval represents</a> &#8220;an incremental win for Moderna, especially considering HHS Secretary Robert F. Kennedy Jr.&#8217;s negative public opinion on mRNA COVID-19 vaccines.&#8221; However, they cautioned that approval alone won&#8217;t massively boost COVID vaccine sales, which depend primarily on overall vaccination market sentiment.
The advisory panel restructuring creates regulatory uncertainty for vaccine manufacturers. Kennedy&#8217;s broader policy changes include removing COVID vaccines from <a href="https://www.benzinga.com/government/regulations/25/05/45688464/rfk-jr-drops-covid-vaccine-recommendation-for-healthy-kids-but-experts-warn-of-major-risks">recommended schedules for healthy children and pregnant women</a>, plus terminating Moderna&#8217;s $600 million bird flu vaccine contract.
RSV hospitalizes 15,000-20,000 U.S. adults aged 50-59 annually. Competing vaccines from Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and GSK plc (LSE: GSK) also target similar demographics, intensifying market competition amid shifting federal oversight. Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45919626/coinbase-ceo-brian-armstrong-teases-crypto-credit-card-powered-by-american-express-bitcoin-cashbacks-offered-but-heres-the-catch">Coinbase CEO Brian Armstrong Teases Crypto Credit Card Powered By American Express—Bitcoin Cashbacks Offered, But Here&#8217;s The Catch</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Lutsenko_Oleksandr / Shutterstock.com

MRNA

FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up

U.S. stocks could open on a negative note on Friday after closing higher on Thursday. The decline comes amid Israel's pre-emptive strikes on Iran and retaliatory attacks from Iran, raising concerns about a further rise in tensions in the Middle East, impacting supply routes.
President Donald Trump once again threatened to impose unilateral tariffs within two weeks if the U.S.'s trade partners don't agree to a deal.
"At a certain point, we're just going to send letters out. And I think you understand that, saying this is the deal, you can take it or leave it," Trump told reporters at the John F. Kennedy Center for the Performing Arts.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.43%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.21%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.18%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.74%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) declined 1.23% to $596.34 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) declined 1.49% to $525.73, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data</a>.
Cues From Last Session:
U.S. stocks ended Thursday on a mixed note, with the major indices in the green and the Russell 2000 ending in the red.
Crude oil surged to over $73 amid the Israel-Iran conflict.
Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) declined by nearly 5% after an Air India <a href="https://www.benzinga.com/markets/25/06/45911791/boeing-dreamliner-carrying-over-200-passengers-crashes-shortly-after-takeoff-near-indias-ahmedabad-b">Boeing 787-8 Dreamliner</a> carrying over 200 passengers crashed on Thursday near the Ahmedabad airport in India.
Most sectors on the S&amp;P 500 closed on a positive note, with only consumer discretionary, industrials, and communication services ending lower. Utilities, information technology and health care recorded the highest increase.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.24%</td>
<td>19,662.48</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.38%</td>
<td>6,045.26</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.24%</td>
<td>42,967.62</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.38%</td>
<td>2,140.09</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
While equities could bear the brunt of an increase in geopolitical risks and tensions in the Middle East due to the Israel-Iran conflict, analysts <a href="https://think.ing.com/articles/fx-daily-geopolitical-risk-storms-back-into-the-picture/">at</a> ING said that this could create some room for a brief rebound in the U.S. dollar.
"In other conditions, the DXY rally would likely be much larger than the roughly 0.75% rebound from the overnight lows we have seen so far, because the dollar would also benefit from the negative shock in equities and bonds," the research firm said.
The main concern, though, is a spike in oil prices. ING analysts highlighted that an energy price shock could force the Jerome Powell-led Federal Reserve to maintain its cautious stance on interest rate policy, which is something that has irked President Trump and others in his administration.
Upcoming Economic Data
Friday's major economic updates include:
<ul class="wp-block-list">
<li>The preliminary consumer sentiment data for June will be announced at 10:00 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>): The digital media company reported record revenue in Q2, beating Wall Street expectations. It raised the full-year revenue guidance to $23.50 billion &#8211; $23.60 billion, from $23.30 billion &#8211; $23.55 billion.</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), General Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>): Boeing CEO Kelly Ortberg skipped the Paris Airshow, while GE delayed its investor day after the deadly Air India crash took the lives of 241 people.</li>
<li>Chime Financial Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHYM#NASDAQ">CHYM</a>): Chime stock closed 37% higher on Thursday following a blockbuster debut on the bourses.</li>
<li>Investors are awaiting earnings results from&nbsp;MoneyHero Ltd.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNY#NASDAQ">MNY</a>) today.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 7.14% to hover around $72.90 per barrel.
Spot prices of gold rose 1.14% to hover around $3,425.35 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was up by 0.33% at the 98.2400 level.
The 10-year Treasury note yield was slightly down by 0.01%.
All of the major Asian markets were in the red on Friday, with the Taiwan Weighted index plunging the most at 0.97%, followed by the Nikkei 225, which fell 0.90%. Similarly, European markets were in the red at the time of writing.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/market-summary/25/06/45918802/middle-east-tensions-rattle-markets-us-stock-futures-slide-oil-jumps-8-gold-surges-above-3400-after-israel-strikes-iran">Middle East Tensions Rattle Markets: US Stock Futures Slide, Oil Jumps 8%, Gold Surges Above $3,400 After Israel Strikes Iran</a></li>
</ul>
Photo courtesy: godongphoto / Shutterstock.com

Equities

ADBE

CHYM

US Stocks Likely To Open Lower As Israel Strikes Iran: Geopolitical Risks Offers Upside For Dollar, Say Experts

Penny Stocks

Press Releases

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Earnings

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Comments

CARISMA Therapeutics

CARISMA Therapeutics (CARM) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル